Weekly Endocrinology Research Analysis
This week’s endocrinology literature highlights three high-impact pieces: a large multicenter RCT shows PGT-A does not improve live birth rates in ICSI for severe male infertility while reducing miscarriage; a mechanistic Diabetologia study identifies ENPP2 and the LPA–LPAR2–Akt/mTOR axis as a promising beta‑cell compensatory target; and a prespecified exploratory analysis of the SELECT trial finds weekly semaglutide 2.4 mg reduces total hospitalizations and inpatient days in people with obesity
Summary
This week’s endocrinology literature highlights three high-impact pieces: a large multicenter RCT shows PGT-A does not improve live birth rates in ICSI for severe male infertility while reducing miscarriage; a mechanistic Diabetologia study identifies ENPP2 and the LPA–LPAR2–Akt/mTOR axis as a promising beta‑cell compensatory target; and a prespecified exploratory analysis of the SELECT trial finds weekly semaglutide 2.4 mg reduces total hospitalizations and inpatient days in people with obesity and established cardiovascular disease without diabetes. Together these reports influence reproductive practice, suggest a tractable beta‑cell regenerative target, and extend GLP‑1RA value to health‑system outcomes.
Selected Articles
1. Preimplantation genetic testing for aneuploidy versus no genetic testing in couples undergoing intracytoplasmic sperm injection for severe male infertility: multicentre, open label, randomised controlled trial.
In a multicentre RCT of 450 couples undergoing ICSI for severe male factor infertility, PGT‑A did not increase live birth rates after the first embryo transfer or cumulatively over 12 months, though it reduced pregnancy loss after the first transfer. The trial was randomized, intention‑to‑treat, and prospectively registered.
Impact: Large, high‑quality RCT in BMJ directly addresses a contentious, high‑cost ART practice and will likely inform guideline and funding decisions around routine PGT‑A use in severe male factor ICSI.
Clinical Implications: Do not assume routine PGT‑A increases live birth for severe male factor ICSI; weigh cost, embryo biopsy risks, and the isolated benefit of reduced miscarriage when counseling couples and setting ART policy.
Key Findings
- No difference in live birth after first embryo transfer: 48.4% (PGT‑A) vs 46.2% (no PGT‑A); OR 1.09, P=0.64.
- No difference in cumulative live birth within 12 months: 60.4% vs 60.9%; P=0.92.
- PGT‑A reduced pregnancy loss after first transfer.
2. Phosphodiesterase ENPP2, which is co-upregulated in obese and pregnant mice, is essential for islet beta cell compensation during obesity.
Using scRNA‑seq, in vitro manipulation, and transgenic/knockout mouse models, the study identifies ENPP2 as a pro‑proliferative regulator of beta‑cell compensation, acting via LPA–LPAR2–Akt/mTOR signaling. ENPP2 overexpression enhances proliferation and insulin secretion while knockout impairs compensation on high‑fat diet; ENPP2 is downregulated in diabetes but induced by estradiol/progesterone.
Impact: Provides a coherent mechanistic pathway linking reproductive hormones, lipid signaling, and β‑cell mass expansion — yielding a druggable target (ENPP2/LPA axis) to potentially slow β‑cell loss in obesity/diabetes.
Clinical Implications: Preclinical now, but ENPP2‑modulating approaches merit prioritization for translational studies and human islet validation as potential strategies to preserve or expand β‑cell mass in obesity‑associated diabetes.
Key Findings
- ENPP2 is highly upregulated in pregnancy and moderately in obesity in beta cells; promotes proliferation, inhibits apoptosis, and enhances GSIS.
- ENPP2 effects mediated through LPA–LPAR2–Akt/mTOR; knockout impairs compensation on high‑fat diet.
- ENPP2 expression is reduced in diabetic models and human T2D samples; co‑induced by estradiol and progesterone.
3. Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.
In the prespecified exploratory analysis of SELECT (n=17,604; median follow‑up 41.8 months), weekly semaglutide 2.4 mg reduced total hospitalizations (mean ratio 0.90) and days hospitalized (rate ratio 0.89) versus placebo in adults with obesity and established CVD but without diabetes, with consistent effects across subgroups.
Impact: Extends GLP‑1RA benefits beyond cardiometabolic event reduction to tangible health‑system outcomes (hospitalizations and inpatient days) in a large global RCT, informing value and policy discussions.
Clinical Implications: Consider semaglutide 2.4 mg for patients with obesity and established CVD (without diabetes) as part of a strategy to reduce hospitalizations; integrate health‑economic analyses and shared decision‑making given exploratory nature of endpoint.
Key Findings
- Total hospitalizations: 18.3 vs 20.4 per 100 patient‑years (mean ratio 0.90; 95% CI 0.85–0.95).
- Days hospitalized: 157.2 vs 176.2 per 100 patient‑years (rate ratio 0.89; 95% CI 0.82–0.98).
- Consistent reductions across major subgroups and for hospitalizations due to serious adverse events.